Approval of Veltassa® in Japan for Hyperkalemia Treatment
Veltassa® is designed to help manage hyperkalemia, a condition characterized by high potassium levels in the blood. Recently, Japan's Ministry of Health and Labor Welfare (MHLW) approved this innovative treatment, making it accessible for adults affected by this serious health issue.
CSL Vifor has teamed up with Zeria Pharmaceutical Co., Ltd. to handle the marketing of Veltassa® in Japan. This partnership has led to impressive results, as Veltassa® is now authorized for use in 41 countries around the globe.
The Importance of Veltassa® in Treating Hyperkalemia
The approval of Veltassa® marks a significant step forward in treating hyperkalemia, especially for those dealing with chronic kidney disease and chronic heart failure. Industry experts estimate that over 300,000 people in Japan suffer from hyperkalemia. This new treatment option is vital for providing effective and tolerable long-term potassium management for these patients.
“We are excited that Veltassa® is available in Japan,” said Hervé Gisserot, the General Manager of CSL Vifor. “This achievement reflects our ongoing commitment to addressing the healthcare needs of patients battling hyperkalemia.” The gratitude expressed by CSL Vifor also emphasizes the teamwork with Zeria, underlining their shared goal of enhancing patient outcomes.
Clinical Evidence and Future Plans
The approval of Veltassa® was supported by extensive clinical data from its development program in Japan, known as ZG-801. Clinical trials showed that this medication effectively controls potassium levels in those diagnosed with hyperkalemia.
Back in 2018, CSL Vifor secured exclusive rights for Zeria to develop and market Veltassa® in Japan. Looking ahead, Zeria plans to kick off marketing efforts for Veltassa® once the National Health Insurance price listing is finalized.
Introducing Hyperkalemia and Veltassa®
Hyperkalemia can lead to serious health issues, with potassium levels exceeding the normal range of 3.5 to 5.0 mmol/L. Although it often shows no immediate symptoms, elevated potassium can lead to serious conditions like heart palpitations, chest pain, and nausea. Common causes of hyperkalemia include chronic kidney disease and heart failure. Additionally, certain heart medications may increase the risk of developing high potassium levels.
Veltassa®, a sodium-free potassium binder, is crucial for effectively lowering potassium levels in patients. It works within the gastrointestinal tract, facilitating the exchange of potassium for calcium, particularly in the colon. By promoting the expulsion of potassium through regular body functions, Veltassa® helps patients maintain healthy potassium levels while allowing them to continue essential life-saving medications.
About CSL Vifor
CSL Vifor is an internationally recognized pharmaceutical company that focuses on innovative therapies for iron deficiency and nephrology. The company prioritizes strategic global partnerships to develop and market products that improve patient care around the world. Based in St. Gallen, Switzerland, CSL Vifor is committed to creating solutions that enable individuals to lead healthier lives.
The parent organization, CSL (ASX: CSL; USOTC: CSLLY), is based in Melbourne and employs about 32,000 people, distributing life-saving therapies in over 100 countries.
Frequently Asked Questions
What is Veltassa® used for?
Veltassa® is used to manage hyperkalemia, a condition characterized by high potassium levels in the blood.
Who will market Veltassa® in Japan?
Zeria Pharmaceutical Co., Ltd. holds the rights to market Veltassa® in Japan.
How does Veltassa® work?
Veltassa® functions as a potassium binder, decreasing potassium levels by exchanging potassium for calcium in the colon.
Why is it important to manage hyperkalemia?
Proper management of hyperkalemia is essential to prevent severe health complications, including heart problems and other symptoms.
In how many countries is Veltassa® available?
Veltassa® has gained marketing approval in 41 countries worldwide, improving patient access to this treatment.
